Aurinia Pharmaceuticals Inc. expected to post earnings of 22 cents a share - Earnings Preview

Aurinia Pharmaceuticals

30/10/2026 14:04

Aurinia Pharmaceuticals Inc. AUPH.OQ AUPH.O is expected to  show a rise in quarterly revenue when it reports  results on November 2 (estimated) for the period ending September 30 2026
The Edmonton Alberta-based  company is expected to report a 13.9% increase in revenue to $83.691 million from $73.47 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc. is for earnings of 22 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc. is $18.00, about 4.6% above its last closing price of $17.21
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
0.25
0.24
0.28
Beat
16.7
Mar. 31 2026
0.21
0.20
0.25
Beat
26.3
Dec. 31 2025
0.22
0.22
0.26
Beat
20​
Sep. 30 2025
0.16
0.16
0.23
Beat
43.8
​​Jun. 30 2025
0.17
0.15
0.16
Beat
9.1
Mar. 31 2025
0.10
0.10
0.16
Beat
60​
Dec. 31 2024
-0.01
-0.02
0.01
Beat
162.5
Sep. 30 2024
0.02
0.02
0.10
Beat
566.7
This summary was machine generated October 30 at 14:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)